Safety and Efficacy of Amiodarone in a Patient With COVID-19

Autor: Carlo Tascini, Alberto Aimo, Nadia Castaldo, Vincenzo Castiglione, Michele Emdin, Cristiano Padalino
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
amiodarone
COVID-19
SARS-CoV-2
medicine.medical_specialty
2019-20 coronavirus outbreak
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
030105 genetics & heredity
Amiodarone
medicine.disease_cause
Article
AEs
adverse events
03 medical and health sciences
0302 clinical medicine
i.v.
intravenous
medicine
Diseases of the circulatory (Cardiovascular) system
COVID-19
COronavirus Disease 19
6MWT
6-minute walking test
Intensive care medicine
Coronavirus
QTc
corrected QT interval
business.industry
Patient affected
CADs
cationic amphiphilic drugs
Hydroxychloroquine
SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus 2
Respiratory failure
RC666-701
LE/Lys
late endosomes/lysosomes
ECG
electrocardiogram
Cardiology and Cardiovascular Medicine
business
PiO2/FiO2
arterial oxygen partial pressure to fractional inspired oxygen ratio
030217 neurology & neurosurgery
medicine.drug
Zdroj: JACC: case reports, 2(9):1307-1310
JACC: Case Reports
Jacc. Case Reports
JACC: Case Reports, Vol 2, Iss 9, Pp 1307-1310 (2020)
Popis: There is an urgent need of effective treatments for COVID-19. Amiodarone, like hydroxychloroquine, exerts antiviral actions by interfering with endocytosis and viral replication. Here we report the first case of a patient affected by respiratory failure related to COVID-19, and recovering after only supportive measures and a short amiodarone course.
Graphical abstract
Databáze: OpenAIRE
Externí odkaz: